



*Effective treatments for  
common skin disorders*

PRESS RELEASE JUNE 18, 2010

## **MOBERG DERMA SIGNS DISTRIBUTION AGREEMENT FOR EMTRIX™ IN ADDITIONAL 8 COUNTRIES**

Moberg Derma AB, Sweden, today announced a commercial agreement for the Middle East. The agreement covers distribution in eight countries for Moberg Derma's novel topical nail product Emtrix™ – a treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Moberg Derma assumes supply responsibility, while the distributor will be responsible for registration and promotion in the Middle East.

Moberg Derma has already entered distribution agreements for the Nordic countries and Canada.

"I am very pleased with the continuation of Emtrix™ international expansion", says Martin Ingman, VP Sales & Marketing.

### **About Emtrix™ and nail fungus**

Emtrix™ is a prescription free, topical nail product and has the potential to become first-line treatment for common nail disorders. Safety and efficacy have been demonstrated in several clinical studies including more than 500 patients. Emtrix™ has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment.

Nail fungus is the most common nail disease and afflicts approximately 10% of the general population and increasing with age. The estimated global market potential exceeds USD 1 billion. The untapped potential is significant since many patients remain untreated. It is generally recognized that there is a need for new efficacious and safe topical treatments.

### **Contact Moberg Derma**

Peter Wolpert, President and CEO

Telephone: +46 8 - 522 307 00

Mobile: +46 70 - 735 71 35

E-mail: [peter.wolpert@mobergderma.se](mailto:peter.wolpert@mobergderma.se)

### **About Moberg Derma**

Moberg Derma AB, Stockholm, Sweden, develops and commercializes patented medical products for the treatment of skin disorders. The company focuses on innovative products based on proven compounds. Moberg Derma outlicenses product rights to partners and distributors while maintaining certain promotion rights. The company began operations at the Karolinska Institute in 2006. The principal owners are Östersjöstiftelsen (the Baltic Sea Foundation), private investors and management. For further information, please visit: [www.mobergderma.se](http://www.mobergderma.se)